"Drug Eruptions" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Adverse cutaneous reactions caused by ingestion, parenteral use, or local application of a drug. These may assume various morphologic patterns and produce various types of lesions.
| Descriptor ID |
D003875
|
| MeSH Number(s) |
C17.800.174.600 C20.543.206.380 C25.100.468.380
|
| Concept/Terms |
Drug Eruptions- Drug Eruptions
- Drug Eruption
- Eruption, Drug
- Eruptions, Drug
- Dermatitis Medicamentosa
- Dermatitis, Adverse Drug Reaction
Morbilliform Drug Reaction- Morbilliform Drug Reaction
- Drug Reaction, Morbilliform
- Drug Reactions, Morbilliform
- Morbilliform Drug Reactions
- Reaction, Morbilliform Drug
- Reactions, Morbilliform Drug
- Maculopapular Exanthem
- Exanthem, Maculopapular
- Exanthems, Maculopapular
- Maculopapular Exanthems
- Morbilliform Exanthem
- Exanthem, Morbilliform
- Exanthems, Morbilliform
- Morbilliform Exanthems
- Maculopapular Drug Eruption
- Drug Eruption, Maculopapular
- Drug Eruptions, Maculopapular
- Eruption, Maculopapular Drug
- Eruptions, Maculopapular Drug
- Maculopapular Drug Eruptions
|
Below are MeSH descriptors whose meaning is more general than "Drug Eruptions".
Below are MeSH descriptors whose meaning is more specific than "Drug Eruptions".
This graph shows the total number of publications written about "Drug Eruptions" by people in this website by year, and whether "Drug Eruptions" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1996 | 1 | 1 | 2 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 1 | 2 |
| 1999 | 0 | 3 | 3 |
| 2001 | 1 | 1 | 2 |
| 2002 | 1 | 1 | 2 |
| 2003 | 2 | 1 | 3 |
| 2004 | 2 | 0 | 2 |
| 2005 | 2 | 1 | 3 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 1 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 3 | 0 | 3 |
| 2010 | 1 | 2 | 3 |
| 2011 | 0 | 1 | 1 |
| 2012 | 4 | 1 | 5 |
| 2013 | 5 | 5 | 10 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 3 | 4 |
| 2016 | 5 | 2 | 7 |
| 2017 | 6 | 5 | 11 |
| 2018 | 7 | 1 | 8 |
| 2019 | 3 | 2 | 5 |
| 2020 | 2 | 1 | 3 |
| 2021 | 3 | 0 | 3 |
| 2022 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
| 2024 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Eruptions" by people in Profiles.
-
Mucocutaneous toxicities from MEK inhibitors: a scoping review of the literature. Support Care Cancer. 2024 Aug 23; 32(9):610.
-
The spectrum of cutaneous toxicities related to novel genitourinary cancer therapies. Crit Rev Oncol Hematol. 2024 Aug; 200:104420.
-
Relevance of Human Herpesvirus 6 Reactivation in Drug Rash With Eosinophilia and Systemic Symptoms. JAMA Dermatol. 2024 Jun 01; 160(6):687.
-
Immunopathogenic Insights on Preferential Human Herpesvirus-6 Reactivation in Drug Rash With Eosinophilia and Systemic Symptoms: A Scoping Review. J Cutan Med Surg. 2023 Jul-Aug; 27(4):388-398.
-
The diverse landscape of dermatologic toxicities of non-immune checkpoint inhibitor monoclonal antibody-based cancer therapy. J Cutan Pathol. 2023 Jan; 50(1):72-95.
-
Ibrutinib skin toxicities: Report of two cases. J Cutan Pathol. 2022 Apr; 49(4):363-368.
-
Diverse landscape of dermatologic toxicities from small-molecule inhibitor cancer therapy. J Cutan Pathol. 2022 Jan; 49(1):61-81.
-
Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers. Invest New Drugs. 2021 06; 39(3):785-795.
-
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors. Support Care Cancer. 2020 Dec; 28(12):6119-6128.
-
Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma. J Cutan Pathol. 2020 Oct; 47(10):954-959.